These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37449930)

  • 1. Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia.
    Najib J; Toderika Y; Dima L
    Am J Ther; 2023 Jul-Aug 01; 30(4):e360-e368. PubMed ID: 37449930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daridorexant in Insomnia Disorder: A Profile of Its Use.
    Nie T; Blair HA
    CNS Drugs; 2023 Mar; 37(3):267-274. PubMed ID: 36754930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daridorexant for the treatment of insomnia disorder: findings and implications.
    Dos Santos JBR; da Silva MRR
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
    Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
    Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
    Dauvilliers Y; Zammit G; Fietze I; Mayleben D; Seboek Kinter D; Pain S; Hedner J
    Ann Neurol; 2020 Mar; 87(3):347-356. PubMed ID: 31953863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
    Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
    CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L
    Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia.
    Park J; Render PharmD KP; Cates PharmD DW
    Ann Pharmacother; 2023 Sep; 57(9):1076-1087. PubMed ID: 36602018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.
    Roch C; Bergamini G; Steiner MA; Clozel M
    Psychopharmacology (Berl); 2021 Oct; 238(10):2693-2708. PubMed ID: 34415378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder.
    Zammit G; Dauvilliers Y; Pain S; Sebök Kinter D; Mansour Y; Kunz D
    Neurology; 2020 May; 94(21):e2222-e2232. PubMed ID: 32341187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis.
    Dutta S; Singhal S; Shah R; Charan J; Dhingra S; Haque M
    Expert Opin Drug Saf; 2023; 22(12):1237-1251. PubMed ID: 37526060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials.
    Jiang F; Li H; Chen Y; Lu H; Ni J; Chen G
    Medicine (Baltimore); 2023 Feb; 102(7):e32754. PubMed ID: 36800596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
    Berger B; Brooks S; Zuiker R; Richard M; Muehlan C; Dingemanse J
    CNS Drugs; 2020 Dec; 34(12):1253-1266. PubMed ID: 33205362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea.
    Boof ML; Dingemanse J; Lederer K; Fietze I; Ufer M
    Sleep; 2021 Jun; 44(6):. PubMed ID: 33305817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study.
    Uchiyama M; Kambe D; Imadera Y; Kajiyama Y; Ogo H; Uchimura N
    Psychopharmacology (Berl); 2022 Jul; 239(7):2143-2154. PubMed ID: 35296912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
    Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
    Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daridorexant: A New Dual Orexin Receptor Antagonist for Insomnia.
    Onge ES; Phillips B; Rowe C
    J Pharm Technol; 2022 Oct; 38(5):297-303. PubMed ID: 36046352
    [No Abstract]   [Full Text] [Related]  

  • 19. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
    Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
    ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.
    Di Marco T; Scammell TE; Meinel M; Seboek Kinter D; Datta AN; Zammit G; Dauvilliers Y
    CNS Drugs; 2023 Jul; 37(7):639-653. PubMed ID: 37477771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.